Sarepta surges as investors cheer expanded use of gene therapy
Adds background on FDA decision in paragraph 4, CEO quote in paragraphs 8 & 9, analyst quote in paragraph 12 & 13
By Mariam Sunny and Bhanvi Satija
June 21 (Reuters) -Sarepta Therapeutics SRPT.O shares surged as much as 40% to a more than three-year high on Friday as an expanded use approval cemented its dominant position in the gene therapy market for Duchenne muscular dystrophy (DMD).
At current levels of $163.88, stock was set to add nearly $4 billion to the company's market value if gains hold.
On Thursday, the U.S. FDA granted traditional approval for the therapy, Elevidys, in patients four years and above who can walk, as well as an accelerated approval for those who cannot.
The health regulator's expanded approval was based on the therapy meeting its secondary goals of improvement in factors like time taken by patients to rise from the floor and a 10-meter walk or run, even though it had failed to meet its primary goal of improving motor functions as assessed by a scoring system.
The FDA decision was the best case scenario predicted by analysts, with BMO Capital Market's Kostas Biliouris estimating that Elevidys could be given to about 13,000 patients, or nearly 90% of U.S. patients.
Given the high demand and acceptable safety, analysts flagged manufacturing concerns and insurance coverage for newly added patients as limiting factors.
The company is working on a new so-called suspension process for commercial production of Elevidys, which could be more beneficial as the therapy moves to a broader outside U.S. population, CEO Doug Ingram said in a conference call with analysts and investors.
"We've already done engineering runs up to 2,000 liters... and it will give us not only more materials down the road years from now, but also significantly reduce the cost of goods," Ingram added.
The company uses Catalent CTLT.N and Thermo Fisher Scientific TMO.N as contract manufacturers for its gene therapy.
Elevidys is among the most expensive treatments in the world with a list price of $3.2 million, and Ingram said on Friday the company does not intend to modify the price.
Sales of the therapy came in at $200.4 million in 2023. BMO's Biliouris said those sales showed that Sarepta had "done an amazing job".
"Commercially, they have been perhaps more successful than any other gene therapy, with the only exception being Zolgensma from Novartis," Biliouris said in an interview ahead of the approval.
Biliouris now expects Elevidys to be the "dominant" DMD gene therapy with no near-term competition until later than 2027.
DMD is an inherited progressive muscle-wasting disorder that affects an estimated one-in-3,500 male births worldwide, according to the U.S.-based National Organization for Rare Disorders.
The decision also follows concerns around an "uphill battle" to secure traditional approval after the therapy failed to meet the main goal in a key confirmatory late-stage trial.
The global treatment market for DMD - including gene therapies and other drugs - is expected to grow to $11.47 billion by 2034, according to ResearchandMarkets.com.
RegenxBio RGNX.O is testing a rival gene therapy in early- to mid-stage, while Pfizer's PFE.N treatment recently failed in a late-stage study.
Sarepta stock performance https://reut.rs/3Vtofsa
Reporting by Mariam Sunny, Bhanvi Satija and Leroy Leo in Bengaluru; Editing by Sriraj Kalluvila and Shailesh Kuber
Activos relacionados
Últimas noticias
Descargo de responsabilidades: Cada una de las entidades de XM Group proporciona un servicio de solo ejecución y acceso a nuestra plataforma de trading online, permitiendo a una persona ver o usar el contenido disponible en o a través del sitio web, sin intención de cambiarlo ni ampliarlo. Dicho acceso y uso están sujetos en todo momento a: (i) Términos y Condiciones; (ii) Advertencias de riesgo; y (iii) Descargo completo de responsabilidades. Por lo tanto, dicho contenido se proporciona exclusivamente como información general. En particular, por favor tenga en cuenta que, los contenidos de nuestra plataforma de trading online no son ni solicitud ni una oferta para entrar a realizar transacciones en los mercados financieros. Operar en cualquier mercado financiero implica un nivel de riesgo significativo para su capital.
Todo el material publicado en nuestra plataforma de trading online tiene únicamente fines educativos/informativos y no contiene –y no debe considerarse que contenga– asesoramiento ni recomendaciones financieras, tributarias o de inversión, ni un registro de nuestros precios de trading, ni una oferta ni solicitud de transacción con instrumentos financieros ni promociones financieras no solicitadas.
Cualquier contenido de terceros, así como el contenido preparado por XM, como por ejemplo opiniones, noticias, investigaciones, análisis, precios, otras informaciones o enlaces a sitios de terceros que figuran en este sitio web se proporcionan “tal cual”, como comentarios generales del mercado y no constituyen un asesoramiento en materia de inversión. En la medida en que cualquier contenido se interprete como investigación de inversión, usted debe tener en cuenta y aceptar que dicho contenido no fue concebido ni elaborado de acuerdo con los requisitos legales diseñados para promover la independencia en materia de investigación de inversiones y, por tanto, se considera como una comunicación comercial en virtud de las leyes y regulaciones pertinentes. Por favor, asegúrese de haber leído y comprendido nuestro Aviso sobre investigación de inversión no independiente y advertencia de riesgo en relación con la información anterior, al que se puede acceder aquí.
